在BCL-2-瘤微环境轴:免疫抑制的机制,耐药性,以及治疗重编程的途径
Abul Vafa1, Barira Rais1, Nishat Afroz2
1Department of Biotechnology, School of Chemical and Life Sciences, Jamia Hamdard, Hamdard Nagar, New Delhi 110062, India.
Critical reviews in oncology/hematology
|November 7, 2025
概括
向抗亡性B细胞淋巴瘤2 (BCL-2) 蛋白质可以重新编程瘤微环境 (TME). 这种方法将TME从免疫抑制转变为免疫反应,增强抗瘤免疫力并克服癌症治疗抵抗力.
科学领域:
- 瘤学和免疫学
- 分子生物学分子生物学
- 癌症治疗方法 癌症治疗方法
背景情况:
- B细胞淋巴瘤2 (BCL-2) 蛋白质家族调节细胞亡,是瘤学的关键治疗标.
- 在瘤微环境 (TME) 中对抗亡的BCL-2成员的升级促进了瘤的生存,免疫逃避和治疗抵抗力.
- 在TME中,缺氧和氧化应激等因素进一步调节BCL-2表达,加强瘤的进展.
研究的目的:
- 审查抗亡BCL-2蛋白质如何维持一种前瘤TME.
- 检查BCL-2在支持免疫抑制细胞和代谢重编程中的作用.
- 突出BCL-2抑制在克服癌症耐药性和增强免疫治疗方面的潜力.
主要方法:
- 在TME中对BCL-2家族信号的文献综述.
- 分析瘤微环境中的分子和细胞相互作用.
- 检查BCL-2家族成员的药理和遗传调制方面的最新进展.
主要成果:
- 抗亡性BCL-2蛋白质支持免疫抑制细胞 (Tregs,MDSCs,TAMs) 并抑制抗瘤免疫力.
- BCL-2家族信号驱动代谢重编程,增强癌细胞的适应性和抵抗力.
- 抑制BCL-2家族成员可以重编程TME,增加免疫反应并加强免疫治疗.
结论:
- 通过与TME相互作用,BCL-2家族的信号传递是维持恶性瘤的组成部分.
- 向BCL-2,BCL-XL或MCL-1可以逆转免疫抑制并增强抗瘤免疫力.
- 抑制BCL-2代表了重塑免疫格局和克服癌症治疗抵抗力的有希望的策略.
关键词:
在BCL-2中.在BCL-XL之间.BH3模仿的是 BH3 的模仿.在MCL-1中.灭症 (apoptosis) 是一种死亡的过程.缺氧 缺氧是指缺氧的情况.瘤微环境是一个微环境.维尼托克拉克斯 (Venetoclax) 是一个更多相关视频
相关概念视频
The Tumor Microenvironment
7.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.6K
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
The Intrinsic Apoptotic Pathway
8.2K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
8.2K
Interactions Between Signaling Pathways
7.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.2K
Cytotoxic T Cells-mediated Immune Response
6.4K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
6.4K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K


